Cardiac AI: Segmenting Diagnostic vs. Preventive for Smarter Investment

The burgeoning field of AI applications in cardiology presents both immense opportunity and significant analytical challenges for investors. Treating all cardiac AI solutions as equal, or even broadly similar, is a fundamental error that leads to misaligned investment theses, underestimation of regulatory hurdles, and in the end, poor capital allocation. A granular understanding of clinical risk, regulatory pathways, and target user intent is paramount to discerning true value and sustainable growth in this complex domain.

The FDA SaMD Framework: A Foundation for Risk Segmentation

The Food and Drug Administration’s (FDA) Software as a Medical Device (SaMD) framework is a critical lens for segmenting cardiac AI solutions. SaMD, defined as software intended for medical purposes that operates independently of hardware, encompasses the vast majority of cardiac AI products. The FDA categorizes SaMD based on its impact on patient care and the significance of the information it provides to healthcare decisions. This risk-based classification directly influences the regulatory burden, development timelines, and in the end, the market potential and exit multiples of a company. Investors should consider the FDA’s classifications as a foundational element of their due diligence.

Class II versus Class III Equivalents: The Regulatory Chasm

The distinction between devices that provide information for clinical management (often Class II) and those that drive definitive diagnostic or treatment decisions (which, depending on risk and novelty, may require a Premarket Approval, PMA, or a De Novo classification to establish a new Class I or II device type) is deep. This isn’t merely a bureaucratic nuance. It dictates the required clinical evidence, post-market surveillance, and the overall cost and timeline to market. For instance, consider the space of consumer-grade electrocardiogram (ECG) software. Companies like AliveCor, with their KardiaMobile devices, operate primarily in the consumer and clinical ECG space. Their AI-powered algorithms analyze ECG rhythms to detect conditions such as atrial fibrillation. While undeniably valuable, these solutions typically fall into a lower-risk category, often achieving 510(k) clearance by demonstrating substantial equivalence to existing predicate devices. The FDA product codes for ECG software reflect this, often being classified as Class II devices, indicating moderate risk. The regulatory pathway here, while rigorous, is generally more simplified than for high-risk diagnostic tools. In stark contrast are solutions like HeartFlow and Cleerly, which focus on advanced diagnostic imaging for coronary artery disease. HeartFlow’s FFRct Analysis, for example, uses AI to create a 3D model of a patient’s coronary arteries from a standard CT scan, simulating blood flow to assess the functional impact of blockages. This provides diagnostic information that directly impacts treatment decisions, potentially obviating the need for invasive procedures. HeartFlow’s FFRct Analysis received a De Novo classification, establishing it as a Class II device with product code PJA, due to the absence of a direct predicate device. Similarly, Cleerly leverages AI to analyze cardiac CT angiography (CCTA) scans, quantifying and characterizing atherosclerotic plaque without requiring invasive procedures. Cleerly ISCHEMIA, for instance, has received 510(k) clearance. Cleerly’s Coronary Artery Disease (CAD) Staging System has also been granted Breakthrough Device Designation by the FDA. While these technologies provide novel, critical diagnostic information, their regulatory pathways can vary, from 510(k) clearance to, for truly novel and higher-risk innovations, a De Novo classification or even a PMA. The FDA considers coronary diagnostic software to be of higher risk, often requiring more extensive clinical validation. This regulatory distinction is not trivial. It impacts everything from the size of clinical trials required to the capital needed for development and the time to achieve market penetration. A company working through a De Novo pathway faces a significantly longer and more expensive journey than one pursuing a 510(k).

Clinical Intent: Diagnostic Certainty vs. Longitudinal Prevention

Beyond regulatory classification, understanding the clinical intent of a cardiac AI solution is important for investors. We can broadly segment these solutions into those aimed at providing definitive diagnostic certainty and those focused on longitudinal prevention and risk management. High-risk diagnostic systems, exemplified by HeartFlow and Cleerly, are designed to deliver a precise diagnosis that directly informs acute clinical decision-making. Their AI models are trained on real patient outcomes data to identify specific pathologies with high accuracy and precision, operating within defined clinical guardrails. The efficacy of such systems must be proven through strong clinical trials, often comparing their diagnostic performance against invasive gold standards. The “AI-native” definition truly comes to bear here: these companies are built from inception around AI as the core diagnostic engine, with published evidence of efficacy underpinning their claims. The value proposition is clear: reduce invasive procedures, improve diagnostic accuracy, and guide appropriate interventions. Conversely, preventive tools, while equally vital, operate on a different risk-reward continuum. Consider solutions that use AI to identify individuals at high risk for future cardiac events, perhaps through continuous monitoring or analysis of routine clinical data. While these tools may not provide a definitive diagnosis of an existing condition, they help proactive intervention and lifestyle modifications. The regulatory pathway for preventive tools can be less arduous if they function as clinical decision support (CDS) that merely informs, rather than diagnoses. However, if they make a direct diagnostic claim, they too will fall under SaMD regulations. The challenge for investors is to differentiate between true AI-native preventive platforms that demonstrably improve patient outcomes over time, and those that are merely “AI-enabled” features bolted onto existing wellness apps. The latter often lack the rigorous clinical validation and real-world outcomes data necessary to secure reimbursement and physician adoption, leading to the creation of zombie companies that struggle to scale.

The “AI-Native” Litmus Test: Beyond the Buzzword

Our definition of an “AI-native” health company is stringent and is a critical filter for investors. It demands three core criteria:

1. Trained on real patient outcomes data: The AI models must learn from actual clinical results, not just theoretical datasets. This ensures their relevance and accuracy in real-world settings.
2. Operating within defined clinical guardrails: The AI’s application must be clearly demarcated, with established boundaries for its use and interpretation, ensuring patient safety and clinical utility.
3. Published evidence of efficacy: Rigorous, peer-reviewed studies demonstrating clinical benefit and accuracy are non-negotiable. This is the bedrock of trust and authority.

Many “AI health apps” fail this test, often relying on rudimentary algorithms, lacking strong clinical validation, or operating outside of regulatory oversight. An “AI-native” approach, conversely, embeds these principles from the ground up. Such companies often benefit from a strong data moat, using proprietary datasets to continuously improve model performance, a key competitive advantage in the long run.

Investor Takeaway: A Risk-Based Taxonomy for Strategic Capital Deployment

For generalist VC partners, a clear risk-based taxonomy is not merely academic. It is essential for evaluating market size, regulatory risk, and potential for reimbursement. Understanding whether a cardiac AI solution is a lower-risk consumer-facing tool like AliveCor’s ECG, or a high-risk, life-altering diagnostic like HeartFlow’s FFRct or Cleerly’s CCTA analysis, dictates the investment thesis. It informs the required capital infusion, the timeline to commercialization, and the potential for a substantial exit. Companies pursuing higher-risk diagnostic pathways, while facing greater upfront investment and regulatory hurdles, often command larger total addressable markets (TAM) and higher reimbursement rates due to their direct impact on clinical outcomes and cost savings within the healthcare system. They are also more likely to secure CPT codes and potentially NTAP (New Technology Add-On Payment) status, significantly de-risking their commercialization. AMA CPT code application process Conversely, lower-risk preventive tools, while potentially scalable more quickly, may struggle with reimbursement and demonstrating long-term clinical impact without strong real-world evidence (RWE). The FDA’s SaMD classification framework, coupled with a deep dive into the clinical intent and the adherence to “AI-native” principles, provides the necessary structured framework for investors to make informed decisions. It allows for a nuanced understanding of the competitive field, distinguishing between genuine innovators and those merely using the “AI” buzzword. Without this clarity, investors risk backing solutions that, despite their technological prowess, may never navigate the complex clinical and regulatory pathways to achieve meaningful impact and generate substantial returns. FDA guidance on SaMD development and regulation